Skip to main content
Caplight Logo









Neurocentrx Pharma

Neurocentrx Pharma

Private
EdinburghHealthcare & Life Scienceshttps://www.neurocentrx.com/

Last Round

Seed

Sep 23, 2025

Total Funding Raised

$5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Neurocentrx Pharma is a biopharmaceutical company developing oral ketamine formulations designed to treat patients with mood disorders and other neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Mental Health, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ketamine therapyabuse-deterrent formulationhome-based caretreatment-resistant depressionpsychedelic medicinedigital prescription safetyrisk evaluation and mitigation strategyREMSbiopharmaceuticalmental health techdrug-plus-softwareclinical-stage pharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurocentrx Pharma Comparables

Compare Neurocentrx Pharma with similar companies based on industry and business-model similarity.

Neurocentrx Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tasman Therapeutics
88%
HMNC Brain Health
85%
AtaiBeckley Inc.
79%

Neurocentrx Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 23, 2025
Series ASep 23, 2025
VC RoundMay 12, 2022
AngelMar 20, 2014

Key People

Founding team and executive leadership

Jeff Roix

Chief Executive Officer

Executive Team

Neurocentrx Pharma Investors

Notable investors and investment history

Neurocentrx Pharma investors
InvestorRounds
o2h venturesVC Round
Equity GapVC Round, Angel
Meltwind AdvisoryVC Round
Old College CapitalVC Round
Neo Kuma VenturesVC Round
Scottish Investment Bank (Scottish Enterprise)VC Round
Wellcome TrustSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 132% MoM.

  • Jul 26, 2026

    Monthly visitors grew 163% MoM, reaching 1.5K.

Neurocentrx Pharma Filings

Explore SEC and related filing metadata, where available.

Neurocentrx Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neurocentrx Pharma's valuation, stock price, and market status.

Is Neurocentrx Pharma a public or private company?

Neurocentrx Pharma is a private company.

What is the current stock price of Neurocentrx Pharma?

Neurocentrx Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Neurocentrx Pharma worth (valuation)?

Valuation information for Neurocentrx Pharma is not publicly available.

Can I buy Neurocentrx Pharma stock?

Neurocentrx Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neurocentrx Pharma's last funding round?

Neurocentrx Pharma's most recent funding round was Series A on September 23, 2025.

Who are the main investors in Neurocentrx Pharma?

Key investors in Neurocentrx Pharma include Wellcome Trust.

Will Neurocentrx Pharma IPO soon?

No public IPO plans have been announced for Neurocentrx Pharma.

How can I track Neurocentrx Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurocentrx Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEdinburgh
Employee Range4
Year Founded2013
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?